Comparative modeling of gastric cancer disparities and prevention in the US and globally

Information

  • Research Project
  • 10330855
  • ApplicationId
    10330855
  • Core Project Number
    U01CA265729
  • Full Project Number
    1U01CA265729-01
  • Serial Number
    265729
  • FOA Number
    RFA-CA-20-043
  • Sub Project Id
  • Project Start Date
    9/15/2021 - 2 years ago
  • Project End Date
    8/31/2026 - 2 years from now
  • Program Officer Name
    SCOTT, SUSAN M
  • Budget Start Date
    9/15/2021 - 2 years ago
  • Budget End Date
    8/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/15/2021 - 2 years ago
Organizations

Comparative modeling of gastric cancer disparities and prevention in the US and globally

Gastric cancer (GC), specifically gastric adenocarcinoma, is the fifth most common cancer and the third leading cause of cancer death globally and has been categorized as a neglected cancer by the World Health Organization. In the U.S., there are stark disparities, with Blacks, Hispanics and Asians having a nearly two- fold greater risk of developing or dying from GC compared to Whites, reflecting differences in risk factors, such as Helicobacter pylori (H. pylori) infection and smoking, as well as access to primary prevention and care. Several factors are changing the landscape of GC prevention, including a better understanding of the disease natural history, new evidence on prevention from prospective studies, and anticipated results from randomized controlled trials. As early GC detection can improve survival by allowing for curative surgical or noninvasive endoscopic resection, new targeted approaches to GC prevention have the potential to markedly improve population health and reduce GC disparities within the U.S. Although H. pylori has been the primary focus of global GC prevention efforts to date, substantial variation by subpopulation in H. pylori prevalence in the U.S. and the world has accentuated the need to optimize H. pylori screen-and-treat interventions for vulnerable groups. One approach is targeted endoscopic screening of high-risk individuals. For instance, persons found to have gastric intestinal metaplasia, a precursor lesion associated with a high progression risk to gastric neoplasia, are recommended to undergo endoscopic surveillance in many countries. A critical need exists to identify effective and cost-effective strategies to address these clinical challenges in the U.S., as well as globally. This proposed work builds upon prior GC work spanning GC and H. pylori simulation modeling studies, GC secondary database analyses, and relevant methodologic and global cancer modeling publications. The research team for this proposal has a vast collective experience in simulation and comparative modeling for cancer control, clinical expertise across the spectrum of GC prevention and care, and a demonstrated track record and commitment to informing cancer care and policy. The proposed three modeling groups are well-positioned to perform and successfully complete the highly relevant project aims. The overarching goal of the proposed research is to produce innovative and paradigm-shifting changes to cancer care through a disparities-focused modeling approach targeting the most vulnerable, high-risk populations that bear the greatest burden of GC in the US, and the world. We will accomplish this goal by performing comparative modeling and completing the following aims: 1) Develop GC simulation models to estimate GC outcomes for subgroups by race and ethnicity in the U.S.; 2) Assess the impact of risk factor trends and primary prevention strategies on GC disparities; 3) Evaluate targeted secondary prevention strategies for reducing early onset-related mortality and GC disparities, and 4) Adapt the models to evaluate GC prevention policies in the global setting.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    U01
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
    717415
  • Indirect Cost Amount
    201780
  • Total Cost
    919195
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    393
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NCI:919195\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    COLUMBIA UNIVERSITY HEALTH SCIENCES
  • Organization Department
    INTERNAL MEDICINE/MEDICINE
  • Organization DUNS
    621889815
  • Organization City
    NEW YORK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    100323725
  • Organization District
    UNITED STATES